Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 445.39M P/E - EPS this Y -2.00% Ern Qtrly Grth -
Income -102.24M Forward P/E -6.91 EPS next Y 34.80% 50D Avg Chg 65.00%
Sales 82.71M PEG - EPS past 5Y - 200D Avg Chg 87.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -21.00%
Recommedations 1.80 Quick Ratio 4.88 Shares Outstanding 34.12M 52W Low Chg 176.00%
Insider Own 10.72% ROA -26.10% Shares Float 24.37M Beta 1.08
Inst Own 66.03% ROE - Shares Shorted/Prior 4.20M/4.25M Price 18.99
Gross Margin 88.68% Profit Margin -123.61% Avg. Volume 543,385 Target Price 38.50
Oper. Margin -62.09% Earnings Date May 9 Volume 1,005,132 Change -6.45%
About UroGen Pharma Ltd.

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

UroGen Pharma Ltd. News
04/22/24 Pharming Group (PHAR) Surges 7.2%: Is This an Indication of Further Gains?
04/17/24 UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers
04/15/24 UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
04/14/24 UroGen Pharma Ltd.'s (NASDAQ:URGN) high institutional ownership speaks for itself as stock continues to impress, up 11% over last week
04/03/24 UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals
03/17/24 UroGen Pharma Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line
03/15/24 UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2023 Earnings Call Transcript
03/14/24 UroGen Pharma Ltd (URGN) Reports Solid JELMYTO Growth Amidst Financial Challenges
03/14/24 Urogen Pharma (URGN) Reports Q4 Loss, Tops Revenue Estimates
03/14/24 UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102
03/08/24 UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/04/24 UroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024
02/26/24 UroGen Pharma to Present at TD Cowen 44th Annual Health Care Conference
02/23/24 Nurix Therapeutics, Inc. (NRIX) Surges 5.1%: Is This an Indication of Further Gains?
02/01/24 UroGen Pharma to Participate at Upcoming Investor Conferences
01/24/24 UroGen Initiates Submission of a Rolling NDA to the FDA for UGN-102
01/17/24 UroGen Secures Exclusive License from medac GmbH to Develop a Next-Generation Novel Mitomycin-Based Formulation for Urothelial Cancers
01/11/24 UroGen Pharma to Participate in the B. Riley Healthcare Conference
11/27/23 Shareholders in UroGen Pharma (NASDAQ:URGN) are in the red if they invested five years ago
11/15/23 UroGen Pharma Ltd. (NASDAQ:URGN) Q3 2023 Earnings Call Transcript
URGN Chatroom

User Image Target_Trader Posted - 04/25/24

$URGN gap fill at 12 waiting to load their

User Image G101SPM Posted - 04/25/24

@satsandstocks per request: $URGN at $13.98 carries SPM 81.25 suggestion neural reading; $DAWN at $13.25 carries SPM 78.99 tag.

User Image satsandstocks Posted - 04/25/24

$URGN This keep coming back into $14 range - impressed ! Heavy into it

User Image sem__sem Posted - 04/23/24

@Numbersandfacts @benji1298 Respect! I started my share holding 2019 March and bought $URGN and it just went down and down until last summer when BO rumours arrived and made a nice win. I still have it but just a tiny position. Due to averaging down my position grew to 1 of the biggest of my portfolio - a bit same like with $MCRB but here I only started 5 months ago..

User Image YungBull100 Posted - 04/22/24

$URGN another week, another Jelmyto dispensed at the hospital. Keep those revs comin

User Image AboveTheHorizon Posted - 04/20/24

$URGN fire sale here Friday and the week before. This is worth $38-$60. Also on top BO list for this year. Accumulate in these low ranges.

User Image Stock_Titan Posted - 04/17/24

$URGN UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers https://www.stocktitan.net/news/URGN/uro-gen-announces-new-data-presentations-at-the-american-urological-4to7y2ocb89l.html

User Image AboveTheHorizon Posted - 04/15/24

$URGN wen buy out $60

User Image Cellphones6213 Posted - 04/15/24

$URGN I’m having a great day

User Image Cellphones6213 Posted - 04/15/24

$URGN look at this volume! I mean not a lot for some stocks but for this one lots of fun!

User Image satsandstocks Posted - 04/15/24

$URGN i just feel like adding more here 14.50 - but that might be my over exposure. Will wait to see how it closes.

User Image UBER_ONE Posted - 04/15/24

$SNGX $URGN FDA !!!!!! Congratulation

User Image UBER_ONE Posted - 04/15/24

$URGN

User Image DonCorleone77 Posted - 04/15/24

$URGN UroGen Pharma announces FDA acceptance of UGM-103 IND UroGen Pharma announced the FDA accepted the company's investigational new drug, or IND, application for UGN-103, a next-generation novel mitomycin-based formulation for low-grade intermediate-risk non-muscle invasive bladder cancer.

User Image UBER_ONE Posted - 04/15/24

$ONVO $SNGX $URGN 3 TOP RUNNER today

User Image RonIsWrong Posted - 04/15/24

$URGN UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

User Image UBER_ONE Posted - 04/15/24

$SNGX another FDA Grants $URGN

User Image Stock_Titan Posted - 04/15/24

$URGN UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer https://www.stocktitan.net/news/URGN/uro-gen-announces-fda-acceptance-of-investigational-new-drug-aeooznlx8mtd.html

User Image Paul_Volcker Posted - 04/14/24

$URGN Any news to account for the 3.5X RelVol on Friday? Can't find anything - thanks in advance.

User Image Night_Owl_Biotech Posted - 04/14/24

We've been following $URGN since Jelmyto was first approved in April 2020. It is often rumored URGN is about to be acquired. On March 25, 2024 URGN shot up 16% at the open (we guessed due to an imminent transaction). Just last Friday April 12, 2024 URGN shot up again 14% on an otherwise dismal day for biotech. The attachment is a simple snapshot of URGN trading over the last 6 weeks or so. We have no idea if URGN is about to be acquired. However, for those who like volatility, if no announcement comes tomorrow morning then it is likely URGN trading will be volatile (either much higher or lower). Good luck. This is not investment advice. Our attachment could be misleading or outright inaccurate. We will soon post a simple revenue multiple driven (potential) valuation analysis of $DAWN

User Image Night_Owl_Biotech Posted - 04/14/24

Attached (left) = all acquisitions of comm'l-stage non-oncology biopharmas acquired since 1/1/17. It's our non-professional experience most new therapies are acquired within 1 to 2 years post approval. We do not recall many acquisitions of comm'l-stage bios w/approvals post 3 years (pls lets us know if we are missing any). (Right) = all non-oncology bios with a FDA approval over the last 4 years (market cap $100MM+). If we had to guess (for entertainment), we suspect $VALN would be acquired sooner rather than later since Pfizer already owns a good piece of VALN & VALN's new vaccine should be a good fit. VALN cash includes $103MM from the sale of PRV. Takeda sells Vonoprazan in Japan making $PHAT an obvious candidate. $TARS is 1 of the best performers in biopharma the last 12 months (excl. recent financing). Next step is a B/O (a guess). Last, watch $URGN as Friday's trading was highly unusual. B/O candidate? This is not investment advice. Be careful, our data may be wrong too.

User Image RonIsWrong Posted - 04/13/24

$URGN bought a bunch back yesterday as well. Gracias, @WSRX

User Image Sduteil Posted - 04/12/24

$URGN Almost 8K shares traded after hours so far….highly unusual for this stock… Horrible day for stocks and this moving hard in a good way.

User Image Stocksrunner Posted - 04/12/24

As the trading week comes to a close, we saw several companies stage impressive rallies from their opening prices to end the day much higher. Here's a rundown of the top performers: $YYAI - Opened at $1.02 and closed at $1.50, a remarkable 47.06% surge. $CNEY - Climbed from an opening of $0.99 to a closing price of $1.16, a 17.17% gain. $ADPT - Saw a 16.22% increase, rising from $2.59 at the open to $3.01 at the close. $URGN - Jumped 15.36% on the day, starting at $13.09 and finishing at $15.10. $XFOR - Ended 10.74% higher than its $1.21 open, closing at $1.34. Keep an eye on these movers for potential opportunities in the market! 📈💼

User Image Sduteil Posted - 04/12/24

$URGN Checkout the volume today… 1.2 million ! Way above 90 day average. Not going to say it but big volume out of the blue on a Friday.. end of day…. Smells very familiar. GLTA.

User Image Sduteil Posted - 04/12/24

$URGN Well, well, well! What a nice day finally for URGN! Had to average down this past week! This is a hidden gem IMO! This has takeout written all over it! I just keep adding.

User Image Cellphones6213 Posted - 04/12/24

$URGN I am so long on this stock it’s not even funny. But just for the sake of a swing trade: it has a huge fda approval date approaching in the next 12 months, and when the phase 3 trials for said drug had good results this stock climbed to $24. Just imagine the run up when that date is announced. Very exciting!

User Image AboveTheHorizon Posted - 04/12/24

$URGN Thanks for heads up on this yesterday @WSRX

User Image CH_Expat Posted - 04/12/24

$URGN Green for the first time after three buys. More please.

User Image WSRX Posted - 04/11/24

$URGN such a steal down here

Analyst Ratings
HC Wainwright & Co. Buy Apr 18, 24
HC Wainwright & Co. Buy Apr 4, 24
HC Wainwright & Co. Buy Mar 18, 24
Oppenheimer Outperform Mar 15, 24
Oppenheimer Outperform Nov 15, 23
HC Wainwright & Co. Buy Oct 4, 23
HC Wainwright & Co. Buy Aug 14, 23
HC Wainwright & Co. Buy Aug 1, 23
Goldman Sachs Neutral Jul 31, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Smith Jason Drew General Counsel General Counsel Jan 31 Sell 15.78 4,993 78,790 23,414 02/05/24
Schoenberg Mark Chief Medical Office.. Chief Medical Officer Jan 31 Sell 15.78 3,789 59,790 151,437 02/05/24
Nussbaum Ran Director Director Jun 06 Option 5 1,030 5,150 1,434,958 02/28/23
Nussbaum Ran Director Director Oct 21 Option 5.94 47,999 285,114 1,485,168 02/28/23
Nussbaum Ran Director Director Jun 16 Option 5 2,211 11,055 1,437,169 02/28/23
Schoenberg Mark Chief Medical Office.. Chief Medical Officer Jan 20 Option 5 122,677 613,385 146,627 01/23/23
Belldegrun Arie Director Director Sep 14 Option 5 160,000 800,000 408,693 09/16/22
Belldegrun Arie Director Director Aug 31 Option 5 3,241 16,205 248,693 09/02/22
Smith Jason Drew General Counsel General Counsel Aug 31 Sell 7.21 3,606 25,999 12,176 09/02/22
Schoenberg Mark Chief Medical Office.. Chief Medical Officer Apr 30 Sell 6.62 254 1,681 23,467 05/03/22
Smith Jason Drew General Counsel General Counsel Jan 31 Sell 7.58 414 3,138 7,449 02/02/22
Barrett Elizabeth A. Chief Executive Offi.. Chief Executive Officer Jan 03 Sell 9.15 46,968 429,757 298,220 01/07/22